Evidence mapPaperPMID 42268557Full record

ArticleMolecular biomedicine2026

Targeted neuronal reprogramming rescues memory and neural synchrony in Alzheimer's disease.

Marcos Galán-Ganga, Irene Rodríguez-Navarro, Sofía Zaballa, Alba Ramón-Lainez, Nerea Gómez-Rivada, Christian Peters, Joaquín Fernández-Irigoyen, Enrique Santamaría, M Ángeles Rabadán, Jordi Alberch and 3 more

Abstract read
In one paragraph

Article in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Marcos Galán-Ganga *Departament de Biomedicina, Facultat de Medicina, Institut de Neurociències, Universitat de Barcelona, Barcelona, 08036, Spain.
Irene Rodríguez-Navarro *Departament de Biomedicina, Facultat de Medicina, Institut de Neurociències, Universitat de Barcelona, Barcelona, 08036, Spain.
Sofía Zaballa *Departament de Biomedicina, Facultat de Medicina, Institut de Neurociències, Universitat de Barcelona, Barcelona, 08036, Spain.
Alba Ramón-LainezDepartament de Biomedicina, Facultat de Medicina, Institut de Neurociències, Universitat de Barcelona, Barcelona, 08036, Spain.
Nerea Gómez-RivadaDepartament de Biomedicina, Facultat de Medicina, Institut de Neurociències, Universitat de Barcelona, Barcelona, 08036, Spain.
Christian PetersDepartment of Molecules-Signaling-Development, Max-Planck Institute for Biological Intelligence, Martinsried, 82152, Germany.
Joaquín Fernández-IrigoyenProteomics Platform, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra UPNA, IdiSNA, Pamplona, 31008, Spain.
Enrique SantamaríaProteomics Platform, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra UPNA, IdiSNA, Pamplona, 31008, Spain.
M Ángeles RabadánZeClinics SL. and ZeNeuroid SL., Barcelona, Spain.
Jordi AlberchDepartament de Biomedicina, Facultat de Medicina, Institut de Neurociències, Universitat de Barcelona, Barcelona, 08036, Spain.
Manuel J RodríguezDepartament de Biomedicina, Facultat de Medicina, Institut de Neurociències, Universitat de Barcelona, Barcelona, 08036, Spain.
Daniel Del Toro *Departament de Biomedicina, Facultat de Medicina, Institut de Neurociències, Universitat de Barcelona, Barcelona, 08036, Spain. danieldeltoro@ub.edu.ORCID http://orcid.org/0000-0002-7416-2155
Albert Giralt *Departament de Biomedicina, Facultat de Medicina, Institut de Neurociències, Universitat de Barcelona, Barcelona, 08036, Spain. albertgiralt@ub.edu.ORCID http://orcid.org/0000-0001-5334-0963

Funding

Fundación Ramón Areces CIVP21A7024Ministerio de Ciencia e Innovación CNS2022 - 135391Ministerio de Ciencia e Innovación PID2024-157024OB-I00
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder and represents a major societal burden. Aging is the strongest risk factor for AD, and partial cellular reprogramming using Yamanaka factors (YFs) has recently emerged as a strategy to counteract age-associated dysfunction. However, the mechanisms by which partial reprogramming ameliorates AD-related phenotypes remain poorly defined. Here, we investigated whether targeted and intermittent expression of YFs in hippocampal neurons restores cognitive function and neural network integrity in the P301S mouse model of tauopathy. We first show that controlled YFs expression in hippocampal neurons increases excitatory synaptic transmission and enhances neural synchrony in GCaMP6-expressing neuronal networks. We then induced intermittent, neuron-specific YFs expression for six months in adult control and P301S mice. This intervention led to a sex-dependent improvement in cognitive and emotional behaviors in P301S mice, accompanied by a reduction in Tau pathology and partial restoration of epigenetic aging markers. At the molecular level, reprogramming restored the composition and signaling of N-methyl-D-aspartate receptor (NMDAR) macro-complexes, including key subunits and AD-associated risk factors such as proline-rich tyrosine kinase 2 (PYK2/PTK2B). Importantly, impaired hippocampal neural synchrony observed in P301S mice was also rescued. Together, these findings demonstrate that targeted, partial in vivo neuronal reprogramming reverses behavioral and network-level deficits in a mouse model of AD and identify NMDAR-associated signaling as a potential mechanistic mediator of this effect.

Indexed as

Alzheimer DiseaseCellular ReprogrammingMemoryNeuronsAnimalsDisease Models, AnimalFemaleFocal Adhesion Kinase 2HippocampusHumansMaleMiceMice, TransgenicReceptors, N-Methyl-D-Aspartatetau ProteinsFocal Adhesion Kinase 2Ptk2b protein, mouseReceptors, N-Methyl-D-Aspartatetau ProteinsAstrocytesDendritic spinesMemoryMicrogliaPYK2Yamanaka factors

Identifiers

PMID42268557
PMCPMC13253944

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.